prompt,outcome,The output reflects the consensus in the scientific and clinical community.,The output contains evidence of correct recall of knowledge.,The output contains evidence of incorrect recall of knowledge.,The output contains evidence of correct reasoning steps.,The output contains evidence of incorrect reasoning steps.,The output contains content it shouldn’t contain.,The output omits content it shouldn’t omit.,The answer contains (novel) concepts that are not typically known in the scientific and clinical community.,I felt qualified to evaluate this topic.,comment,expert,type,explanation,simulation (double click to see everything!),experiment_name,prompt_name,system_name
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,"rapid onset of seizures, loss of consciousness, and cardiac arrest",6,6,1,5,2,2,6,1,6,"A relevant outcome (conditions-driven outcome) shall report the onset of death (within mins? Hours?) per dose of injection (sublethal versus lethally toxic doses) per age of injected mouse (newborn versus adults) per strain of injected mouse (C57BL6 versus NSG versus Balbc versus Fvb...) per gender of mouse (males versus females susceptibility), per mode of exposure... ",expert3,OUT,,,mouse_immunology,generated_Cyanide,high_complexity
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,Tumor growth,6,6,1,5,2,1,6,1,7,"A relevant, novel and useful outcome (conditions-driven outcome) highlight the following details: 1) tumor growth per number of injected cells, 2) tumor growth per strain of mouse (C57BL6J versus NSG versus Balbc versus Fvb …), 3) tumor growth per anatomical site (intrasplenic, intravenous, subcutaneous...), 4) tumor growth kinetic curve as speed of tumor progression per number of injected cells, 5) tumor site and probability of metastasis per site of initial injection ",expert3,OUT,,,mouse_immunology,generated_YUMM_1_7,baseline
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,The wild type mouse develops a melanoma tumor that grows and potentially metastasizes to other organs.,6,6,1,6,2,1,5,1,7,"A relevant, novel and useful outcome (conditions-driven outcome)should highlight the following details: 1) tumor growth per number of injected cells, 2) tumor growth per strain of mouse (C57BL6J versus NSG versus Balbc versus Fvb …), 3) tumor growth per anatomical site (intrasplenic, intravenous, subcutaneous...), 4) tumor growth kinetic curve as speed of tumor progression per number of injected cells, 5) tumor site and probability of metastasis per site of initial injection ",expert3,OUT,,,mouse_immunology,generated_YUMM_1_7,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,Death,5,5,2,3,2,2,6,1,6,"A relevant outcome shall report the onset of death (within mins? Hours?) per dose of injection (sublethal versus lethally toxic doses) per age of injected mouse (newborn versus adults), per gender of mouse (males versus females susceptibility), per mode of exposure",expert3,OUT,,,mouse_immunology,generated_Cyanide,baseline
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,"rapid onset of seizures, loss of consciousness, and cardiac arrest",7,6,2,6,2,2,5,1,6,"An explanation shall firstly discriminate between the effects of lethal and sublethal doses of cyanide exposure, males versus females manifestations, onset of these manifestations, and importantly a systemic overview of symptoms and affected organs beyond the cardiovascular and neurological toxicology (including respiratory, renal, hepatic, GI tract ... as summarized here https://www.atsdr.cdc.gov/ToxProfiles/tp8-c3.pdf)",expert3,EXP,"Cyanide injection inhibits cytochrome c oxidase, leading to decreased ATP production and increased ROS levels. This impairs cellular processes and functions, causing oxidative stress and cellular damage, particularly in the brain and heart. The final outcome is the rapid onset of seizures, loss of consciousness, and cardiac arrest.",,mouse_immunology,generated_Cyanide,high_complexity
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,Tumor growth,6,6,1,6,2,2,5,1,7,"An explanation shall cover the mutational profile of YUMM 1.7 cell lines, the mouse strain of origin (C57BL6J male), the kinetics of tumor growth, the metastatic potential and site ….",expert3,EXP,"YUMM 1.7 is a mouse melanoma cell line derived from a genetically engineered mouse model. When injected into a wild type mouse, these cells can form tumors, leading to tumor growth as the most relevant final outcome.",,mouse_immunology,generated_YUMM_1_7,baseline
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,The wild type mouse develops a melanoma tumor that grows and potentially metastasizes to other organs.,6,6,1,7,1,2,4,1,7,"An explanation shall detail the mutational profile of YUMM 1.7 cell line, the origin of the line (C57BL6J mouse male), the kinetics of growth and shall further detail the site of metastasis with respect to the site of injection  ",expert3,EXP,"The YUMM 1.7 cells are derived from the same mouse strain as the wild type mouse and carry oncogenic mutations that promote tumor growth and progression. The immune system may not be able to effectively eliminate the tumor, allowing it to grow and potentially metastasize.",,mouse_immunology,generated_YUMM_1_7,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,Death,7,5,2,5,2,2,6,1,6,"An explanation shall majorly focus on the ROS mode of toxicity coupled with NO implication and impact on cardiovascular system. As stated above an ideal explanation shall discriminate between the effects of lethal and sublethal doses of cyanide exposure, males versus females manifestations, onset of these manifestations, and importantly a systemic overview of symptoms and affected organs beyond the cardiovascular and neurological toxicology (including respiratory, renal, hepatic, GI tract ... as summarized here https://www.atsdr.cdc.gov/ToxProfiles/tp8-c3.pdf)",expert3,EXP,"Cyanide is a potent toxin that inhibits cellular respiration by binding to cytochrome c oxidase, a key enzyme in the electron transport chain. This prevents cells from producing ATP, leading to a rapid depletion of energy and ultimately causing death in the organism.",,mouse_immunology,generated_Cyanide,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,enhanced innate immune response upon rechallenge with high-dose LPS after 90 days,6,6,2,6,2,2,2,2,6,,expert3,OUT,,,trained_immunity,training_betaglucan,high_complexity
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Tolerance to high-dose LPS,6,6,2,5,2,2,2,2,6,,expert3,OUT,,,trained_immunity,tolerance_LPS,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Enhanced innate immune response,6,6,2,6,2,2,2,2,6,,expert3,OUT,,,trained_immunity,training_betaglucan,baseline
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,The mouse exhibits a reduced innate immune response upon rechallenge with high-dose LPS after 90 days due to the persistence of endotoxin tolerance.,6,6,2,6,2,2,2,2,6,,expert3,OUT,,,trained_immunity,training_LPS,high_complexity
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Attenuated innate immune response,6,6,2,6,2,2,2,2,6,,expert3,OUT,,,trained_immunity,training_LPS,baseline
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,"The innate immune response upon rechallenge with high-dose LPS after 90 days is characterized by reduced responsiveness of macrophages and neutrophils, and potentially altered LPS clearance rates in the spleen and liver.",6,7,2,7,1,2,2,2,6,,expert3,OUT,,,trained_immunity,tolerance_LPS,high_complexity
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,enhanced innate immune response upon rechallenge with high-dose LPS after 90 days,6,6,2,6,2,2,2,2,6,,expert3,EXP,"The previous exposure to beta-glucan is likely to prime the mouse's innate immune system for an enhanced response upon LPS rechallenge. This enhanced response includes increased activation of PRRs, increased production of pro-inflammatory cytokines by DCs and macrophages, and enhanced recruitment and activation of neutrophils and NK cells.",,trained_immunity,training_betaglucan,high_complexity
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Tolerance to high-dose LPS,6,6,2,6,2,2,2,2,6,,expert3,EXP,"Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit tolerance to LPS. This is because the initial exposure to high-dose LPS triggers a strong innate immune response, which leads to the production of pro-inflammatory cytokines and activation of immune cells. Over time, the immune system adapts to the presence of LPS and becomes less responsive to subsequent exposures, a phenomenon known as endotoxin tolerance. This tolerance helps protect the host from excessive inflammation and tissue damage during subsequent exposures to LPS.",,trained_immunity,tolerance_LPS,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Enhanced innate immune response,6,6,2,6,2,2,2,2,6,,expert3,EXP,"Beta-glucan is a known immunomodulator that can prime the immune system, particularly the innate immune response. Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit an enhanced innate immune response due to the previous exposure to beta-glucan. This response may include increased phagocytosis, production of pro-inflammatory cytokines, and activation of immune cells such as macrophages and neutrophils.",,trained_immunity,training_betaglucan,baseline
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,The mouse exhibits a reduced innate immune response upon rechallenge with high-dose LPS after 90 days due to the persistence of endotoxin tolerance.,6,6,2,6,2,2,2,2,6,,expert3,EXP,"The initial low-dose LPS injection likely induces endotoxin tolerance in the mouse's immune cells, leading to a dampened production of pro-inflammatory cytokines upon subsequent high-dose LPS exposure. Although the duration of endotoxin tolerance can vary, it is possible that it persists for 90 days in this case, resulting in a reduced innate immune response.",,trained_immunity,training_LPS,high_complexity
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Attenuated innate immune response,6,7,2,7,2,2,2,2,6,,expert3,EXP,"Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit an attenuated innate immune response. This is due to a phenomenon called endotoxin tolerance, where prior exposure to low-dose LPS can lead to a reduced inflammatory response upon subsequent exposure to higher doses of LPS. This tolerance is a protective mechanism that prevents excessive inflammation and tissue damage. However, the duration of endotoxin tolerance can vary, and it may not be as pronounced after 90 days compared to a shorter time interval.",,trained_immunity,training_LPS,baseline
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,"The innate immune response upon rechallenge with high-dose LPS after 90 days is characterized by reduced responsiveness of macrophages and neutrophils, and potentially altered LPS clearance rates in the spleen and liver.",6,5,2,5,2,2,2,2,6,,expert3,EXP,"The development of endotoxin tolerance after the first high-dose LPS injection leads to a reduced response of the innate immune system to the second LPS challenge, with potential changes in the function of organs involved in LPS clearance.",,trained_immunity,tolerance_LPS,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response",6,5,2,5,2,2,6,2,6,"missing are vasopressors, corticosteroids and the key ""scientific"" term for ""monitoring immune responses) shall be immuno-modulators or recombinant cytokines antagonists (such as anakinra_IL1R antagonist for the personalized management of high-ferritin sepsis)",expert3,OUT,,,sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.",6,5,2,5,2,2,5,2,6,"immunomodulators to boost immune system response (such as IFNg), vasoregulators. The use of corticosteroids here for a sepsis with a reduced immune phenotype might worsen patient's prognosis",expert3,OUT,,,sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.",6,6,2,6,2,2,3,2,6,Vasoregulators and specification of immunomodulators such as use of recombinant cytokines (IFNg) is missing,expert3,OUT,,,sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.",7,7,1,7,1,1,3,2,6,immunomodulators to shut-down exacerbated inflammation such as anakinra (IL-1R antagonist) would have added considerable novelty on a personalized therapeutic approach for the treatment of high-ferritin sepsis,expert3,OUT,,,sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response",6,6,1,7,1,1,5,2,6,"The explanation missed the mentioning of vasopressors (to increase blood pressure) clinically implicated in the therapeutic management of sepsis. The explanation as it already covered the impact of high ferritin levels on exacerbated inflammation, should have highlighted the link between ferritin high levels and worse prognosis. Novelty of the outcome would have been covered with the recent status of using anakinra in the management of macrophage-associated syndrome",expert3,EXP,"The patient has sepsis, which is typically treated with broad-spectrum antibiotics to target the underlying infection. Fluid resuscitation is also important to maintain blood pressure and organ perfusion. High ferritin levels indicate an inflammatory response, and a high percentage of CD45/CD14-monocytes expressing HLA-DR suggests an active immune response. Monitoring the patient's immune response and adjusting treatment as needed is crucial for optimal recovery.",,sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.",6,6,2,6,2,3,5,2,6,"The outcome mentioned corticosteroids for the management of a sepsis characterized by reduced inflammatory response, it is a questioned therapeutic suggestion here! The outcome should mention here, as boosters of immune response, recombinant cytokines such as IFNg or immunomodulators ...",expert3,EXP,"The patient has sepsis, which is a life-threatening condition caused by the body's response to an infection. Low ferritin levels indicate a possible iron deficiency, while a low percentage of CD45/CD14-monocytes expressing HLA-DR suggests an impaired immune response. The recommended treatment for sepsis includes intravenous antibiotics to target the underlying infection, fluids to maintain blood pressure and organ function, and corticosteroids may be considered to modulate the immune response.",,sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.",6,7,2,6,2,2,6,2,6,"The explanation didn't highlight the recommended treatments such as antibiotics, fluids, vaso-regulators … neither explained how this shall help therapy. It failed to further specific immunomodulators such treatment with recombinant cytokines including IFNg",expert3,EXP,"The immunomodulatory therapy can help improve the patient's immune function, reducing the risk of secondary infections and complications related to sepsis. The use of intravenous iron supplementation should be carefully considered due to the potential risks associated with sepsis.",,sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.",6,5,3,5,3,3,6,1,6,The explanation lacked scientific reasoning including the underlying cause and effects of high ferritin levels on inflammation and prognosis ...  Among therapeutic regimens it is missing vasoregulators and anakinra (IL-1R antagonist for the management of myeloid associated phenotype),expert3,EXP,"This combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.",,sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,7,6,2,7,1,2,6,1,6,The outcome upon highlighting potential usage of anakinra (IL-1R antagonist) would have covered novelty in the field of personalized sepsis therapy,expert3,SIM,,"conclusion:
  outcome: Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response
  explanation: The patient has sepsis, which is typically treated with broad-spectrum antibiotics to target the underlying infection. Fluid resuscitation is also important to maintain blood pressure and organ perfusion. High ferritin levels indicate an inflammatory response, and a high percentage of CD45/CD14-monocytes expressing HLA-DR suggests an active immune response. Monitoring the patient's immune response and adjusting treatment as needed is crucial for optimal recovery.
",sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,5,2,5,2,5,6,1,6,"The outcome mentioned low ferritin levels as iron deficiency. It could have further elaborated and detailed the multiple parameters implicated in low ferritin levels. Corticosteroids for the management of sepsis characterized by reduced inflammatory response is a questioned therapeutic suggestion here! The outcome should mention here, as boosters of immune response, recombinant cytokines such as IFNg...",expert3,SIM,,"conclusion:
  outcome: Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.
  explanation: The patient has sepsis, which is a life-threatening condition caused by the body's response to an infection. Low ferritin levels indicate a possible iron deficiency, while a low percentage of CD45/CD14-monocytes expressing HLA-DR suggests an impaired immune response. The recommended treatment for sepsis includes intravenous antibiotics to target the underlying infection, fluids to maintain blood pressure and organ function, and corticosteroids may be considered to modulate the immune response.
",sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,7,7,1,7,1,1,2,2,6,,expert3,SIM,,"parameters:
- patient with sepsis
- low ferritin levels
- low percentage of CD45/CD14-monocytes expressing HLA-DR
simulation:
- step: 1
  level: cellular
  facts: Sepsis is a life-threatening condition caused by the body's response to an infection, leading to systemic inflammation and organ dysfunction [1]. Ferritin is a protein that stores iron and releases it in a controlled manner [2]. Low ferritin levels can indicate iron deficiency or inflammation [3]. CD45/CD14-monocytes are a type of immune cell, and HLA-DR is a major histocompatibility complex (MHC) class II cell surface receptor involved in antigen presentation [4]. A low percentage of CD45/CD14-monocytes expressing HLA-DR is associated with immune dysfunction and increased risk of secondary infections in sepsis [5].
  entities: sepsis, ferritin, CD45/CD14-monocytes, HLA-DR, inflammation, immune dysfunction
  assumptions: The patient's low ferritin levels and low percentage of CD45/CD14-monocytes expressing HLA-DR are related to their sepsis condition.
  consequence: The patient is at risk of worsening sepsis, organ dysfunction, and secondary infections due to immune dysfunction.
  probability: 80
  explanation: The low ferritin levels and low percentage of CD45/CD14-monocytes expressing HLA-DR indicate that the patient's immune system is not functioning optimally, increasing the risk of complications related to sepsis.
  novelty: 0
- step: 2
  level: organism
  facts: Treatment for sepsis typically involves antibiotics to target the underlying infection, intravenous fluids to maintain blood pressure, and vasopressors if necessary [1]. In some cases, immunomodulatory therapies may be considered to address immune dysfunction [6]. Intravenous iron supplementation can be used to treat iron deficiency, but its use in sepsis is controversial due to the potential for increased bacterial growth [7].
  entities: antibiotics, intravenous fluids, vasopressors, immunomodulatory therapies, intravenous iron supplementation
  assumptions: The patient's sepsis is being managed with standard care, including antibiotics and intravenous fluids. Additional treatments may be needed to address the immune dysfunction and low ferritin levels.
  consequence: The patient may benefit from immunomodulatory therapy to improve immune function and reduce the risk of secondary infections.
  probability: 70
  explanation: Immunomodulatory therapy can help address the immune dysfunction associated with the low percentage of CD45/CD14-monocytes expressing HLA-DR, potentially reducing the risk of secondary infections and improving the patient's overall condition.
  novelty: 20
conclusion:
  outcome: The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.
  explanation: The immunomodulatory therapy can help improve the patient's immune function, reducing the risk of secondary infections and complications related to sepsis. The use of intravenous iron supplementation should be carefully considered due to the potential risks associated with sepsis.
references:
  '[1]': Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
  '[2]': 'Arosio P, Ingrassia R, Cavadini P. 2009. Biochim Biophys Acta. Ferritins: A family of molecules for iron storage, antioxidation and more.'
  '[3]': Weiss G, Goodnough LT. 2005. N Engl J Med. Anemia of Chronic Disease.
  '[4]': Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. 2010. J Leukoc Biol. Nomenclature of monocytes and dendritic cells in blood.
  '[5]': Monneret G, Lepape A, Voirin N, et al. 2006. Crit Care Med. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.
  '[6]': 'Hotchkiss RS, Monneret G, Payen D. 2013. Nat Rev Immunol. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.'
  '[7]': 'Litton E, Xiao J, Ho KM. 2013. JAMA. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials.'
",sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,7,7,1,7,1,2,2,2,6,,expert3,SIM,,"parameters:
- patient with sepsis
- high ferritin levels
- high percentage of CD45/CD14-monocytes expressing HLA-DR
simulation:
- step: 1
  level: cellular
  facts: Sepsis is a life-threatening condition caused by a dysregulated host response to infection, leading to systemic inflammation and organ dysfunction [1]. Ferritin is an iron storage protein, and its levels can increase during inflammation and infection [2]. CD45/CD14-monocytes are a subset of immune cells involved in the innate immune response, and HLA-DR is a major histocompatibility complex (MHC) class II molecule involved in antigen presentation to T cells [3]. High HLA-DR expression on monocytes is associated with an activated immune response [4].
  entities: sepsis, ferritin, CD45/CD14-monocytes, HLA-DR, inflammation, infection, immune response
  assumptions: The patient's high ferritin levels and high percentage of CD45/CD14-monocytes expressing HLA-DR indicate an ongoing inflammatory response and activated immune system.
  consequence: The patient may require treatment to manage the sepsis and reduce the inflammatory response.
  probability: 90
  explanation: The presence of sepsis, high ferritin levels, and activated monocytes suggest that the patient's immune system is responding to an infection, and treatment is needed to manage the sepsis and inflammation.
  novelty: 0
- step: 2
  level: organ/systemic
  facts: The management of sepsis involves a combination of supportive care, antimicrobial therapy, and targeted interventions to address the underlying infection and organ dysfunction [1]. Early administration of broad-spectrum antibiotics is crucial in sepsis treatment [5]. Fluid resuscitation and vasopressor therapy may be needed to maintain adequate blood pressure and organ perfusion [6]. In some cases, immunomodulatory therapies, such as corticosteroids, may be used to modulate the inflammatory response [7].
  entities: supportive care, antimicrobial therapy, targeted interventions, broad-spectrum antibiotics, fluid resuscitation, vasopressor therapy, corticosteroids
  assumptions: The patient's sepsis requires a combination of treatments to address the infection, inflammation, and organ dysfunction.
  consequence: The recommended treatment for the patient includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.
  probability: 95
  explanation: The combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.
  novelty: 0
conclusion:
  outcome: The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.
  explanation: This combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.
references:
  '[1]': Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
  '[2]': Kell DB, Pretorius E. 2014. Front Pharmacol. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells.
  '[3]': 'Ziegler-Heitbrock L. 2007. Immunobiology. The CD14+ CD16+ blood monocytes: their role in infection and inflammation.'
  '[4]': 'Docke WD, Randow F, Syrbe U, et al. 1997. Nat Med. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.'
  '[5]': 'Rhodes A, Evans LE, Alhazzani W, et al. 2017. Intensive Care Med. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.'
  '[6]': Cecconi M, De Backer D, Antonelli M, et al. 2018. Intensive Care Med. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine.
  '[7]': 'Annane D, Bellissant E, Bollaert PE, et al. 2009. JAMA. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.'
",sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,6,2,6,2,6,5,2,6,The outcome based on logic reasoning highlighted potential usage of GM-CSF and iron supplements for treating sepsis with low ferritin-Yet bulk of trials revealed unfavorable outcomes particularly upon iron intake. The outcome failed to highlight novel regimens to counteract immunoparalysis such as recombinant IFNg,expert3,SIM,,"simulation:
  - step: 1
    level: cellular
    consequence: impaired immune response
    probability: 90
    explanation: Low ferritin levels indicate low iron storage, which can impair the immune system's ability to fight infections. A low percentage of CD45/CD14-monocytes expressing HLA-DR suggests a weakened immune response, as HLA-DR is crucial for antigen presentation and activation of T cells.
  - step: 2
    level: organ
    consequence: increased risk of organ dysfunction
    probability: 80
    explanation: In sepsis, the impaired immune response can lead to uncontrolled infection and inflammation, increasing the risk of organ dysfunction and failure.
  - step: 3
    level: organism
    consequence: need for targeted treatment
    probability: 95
    explanation: Given the patient's low ferritin levels and weakened immune response, targeted treatment is necessary to address the underlying infection, support the immune system, and prevent further complications.

conclusion:
  outcome: administration of antibiotics, iron supplementation, and immune-modulating therapy
  explanation: The recommended treatment for this patient would include the administration of broad-spectrum antibiotics to target the underlying infection, iron supplementation to address the low ferritin levels, and immune-modulating therapy (such as granulocyte-macrophage colony-stimulating factor, GM-CSF) to improve the percentage of CD45/CD14-monocytes expressing HLA-DR and enhance the immune response. This combined approach would aim to control the infection, support the patient's immune system, and reduce the risk of organ dysfunction.",sepsis_treatment,sepsis_immunoparalysis,low_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,7,7,1,6,2,1,2,2,6,The outcome upon highlighting potential usage of anakinra (IL-1R antagonist) would have covered novelty in the field of personalized sepsis therapy,expert3,SIM,,"simulation:
  - step: 1
    level: cellular
    consequence: activation of monocytes and macrophages
    probability: 90
    explanation: In sepsis, the presence of high ferritin levels and a high percentage of CD45/CD14-monocytes expressing HLA-DR indicates an ongoing immune response. CD14 is a marker for monocytes, and HLA-DR is a major histocompatibility complex (MHC) class II molecule involved in antigen presentation. The increased expression of HLA-DR suggests that monocytes and macrophages are activated and presenting antigens to T cells.

  - step: 2
    level: organ
    consequence: systemic inflammation
    probability: 85
    explanation: The activation of monocytes and macrophages in sepsis leads to the release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines contribute to systemic inflammation, which can cause multi-organ dysfunction and potentially lead to septic shock.

  - step: 3
    level: organism
    consequence: stabilization of the patient's condition
    probability: 80
    explanation: In order to treat sepsis, the primary goal is to stabilize the patient's condition by addressing the underlying infection and managing the systemic inflammation. This may involve the use of broad-spectrum antibiotics, fluid resuscitation, vasopressors, and supportive care measures, such as mechanical ventilation and renal replacement therapy if necessary.

  - step: 4
    level: molecular
    consequence: modulation of immune response
    probability: 75
    explanation: In addition to the standard sepsis treatment, targeting the immune response may be beneficial in this case due to the high ferritin levels and increased HLA-DR expression on CD45/CD14-monocytes. Immunomodulatory therapies, such as corticosteroids or intravenous immunoglobulin (IVIG), can help modulate the immune response and reduce excessive inflammation.

conclusion:
  outcome: recommendation of standard sepsis treatment and immunomodulatory therapy
  explanation: Based on the simulation, the recommended treatment for this patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR would be a combination of standard sepsis treatment (antibiotics, fluid resuscitation, vasopressors, and supportive care) and immunomodulatory therapy (corticosteroids or IVIG) to address the underlying infection, manage systemic inflammation, and modulate the immune response.",sepsis_treatment,sepsis_hyperinflammation,low_complexity
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","survival_relative_to_median: increased
survival_deviation_months: 6
",6,6,2,6,2,1,1,2,6,,expert3,OUT,,,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,baseline
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","increased survival, +4 months",6,6,2,6,2,1,1,2,6,,expert3,OUT,,,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,high_complexity
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","survival_relative_to_median: increased
survival_deviation_months: 6
",7,7,1,7,1,2,5,1,6,"The explanation missed highlighting apart from MGMT methylation and its correlation with temozolomide chemotherapeutic response, EGFR mutation targeted therapy by the FDA ERA-801. It should further elaborate how the absence of the other mutations (Trp53, PI3K...) would yield a favorable prognostic outcome: pronounced cell death post-therapy, reduced therapy- induced senescence and its detrimental effects, reduced tumor cells growth, proliferation ...",expert3,EXP,"The patient has mutations in PTEN and EGFR, which are commonly associated with glioblastoma. However, the high MGMT methylation status suggests a better response to temozolomide, a standard-of-care chemotherapy drug. This factor may increase the patient's survival relative to the median overall glioblastoma survival. The absence of mutations in TP53, PIK3CA, NF1, MUC16, and RB1 may also contribute to a more favorable prognosis. Based on these factors, the patient's survival is estimated to be increased by 6 months relative to the median survival of 15 months.",,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,baseline
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","increased survival, +4 months",6,7,1,6,2,2,6,1,6,"It should further elaborate how the absence of the other mutations (Trp53, PI3K...) would yield a favorable prognostic outcome: pronounced cell death post-therapy, reduced therapy- induced senescence and its detrimental effects, reduced tumor cells growth, proliferation ...",expert3,EXP,"The patient's survival is more likely to be increased relative to the median overall glioblastoma survival (15 months) due to the high MGMT methylation status, which improves the response to temozolomide treatment, and the potential use of genotype-informed treatment, such as EGFR inhibitors. The survival is estimated to deviate from the median by 4 months, resulting in a total survival of 19 months.",,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,"rapid onset of seizures, loss of consciousness, and cardiac arrest",7,7,1,7,1,1,1,1,5,"this output is more specific and than more prone to error, I am not sure wheter these are the steps after cynide injection",expert2,OUT,,,mouse_immunology,generated_Cyanide,high_complexity
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,Tumor growth,7,7,1,7,1,1,2,1,7,"yes, rather general but definetly correct",expert2,OUT,,,mouse_immunology,generated_YUMM_1_7,baseline
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,The wild type mouse develops a melanoma tumor that grows and potentially metastasizes to other organs.,7,7,1,6,2,1,5,1,7,"yes, also true but the prompt is somehow general because it mentions  ""injections"" without specifying what type of injection (e.g. subcutanoesu injections will not lead to metastasis most likely; while Intravenous injections will) so it is hard to evaluate if the output is correct",expert2,OUT,,,mouse_immunology,generated_YUMM_1_7,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,Death,7,7,1,6,2,1,2,1,5,this is less specific respect to raw 5 and this makes it easier to be correct,expert2,OUT,,,mouse_immunology,generated_Cyanide,baseline
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,"rapid onset of seizures, loss of consciousness, and cardiac arrest",7,7,1,7,1,1,1,1,5,,expert2,EXP,"Cyanide injection inhibits cytochrome c oxidase, leading to decreased ATP production and increased ROS levels. This impairs cellular processes and functions, causing oxidative stress and cellular damage, particularly in the brain and heart. The final outcome is the rapid onset of seizures, loss of consciousness, and cardiac arrest.",,mouse_immunology,generated_Cyanide,high_complexity
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,Tumor growth,7,7,1,7,1,1,5,1,7,"I think mentioning that the immune system does not recognize the tumor is important, in this output is not reported",expert2,EXP,"YUMM 1.7 is a mouse melanoma cell line derived from a genetically engineered mouse model. When injected into a wild type mouse, these cells can form tumors, leading to tumor growth as the most relevant final outcome.",,mouse_immunology,generated_YUMM_1_7,baseline
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,The wild type mouse develops a melanoma tumor that grows and potentially metastasizes to other organs.,7,7,1,7,1,1,1,1,7,,expert2,EXP,"The YUMM 1.7 cells are derived from the same mouse strain as the wild type mouse and carry oncogenic mutations that promote tumor growth and progression. The immune system may not be able to effectively eliminate the tumor, allowing it to grow and potentially metastasize.",,mouse_immunology,generated_YUMM_1_7,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,Death,7,7,1,7,1,1,1,1,5,,expert2,EXP,"Cyanide is a potent toxin that inhibits cellular respiration by binding to cytochrome c oxidase, a key enzyme in the electron transport chain. This prevents cells from producing ATP, leading to a rapid depletion of energy and ultimately causing death in the organism.",,mouse_immunology,generated_Cyanide,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,enhanced innate immune response upon rechallenge with high-dose LPS after 90 days,6,6,1,7,1,1,1,1,5,,expert2,OUT,,,trained_immunity,training_betaglucan,high_complexity
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Tolerance to high-dose LPS,6,6,1,7,1,1,1,1,5,,expert2,OUT,,,trained_immunity,tolerance_LPS,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Enhanced innate immune response,6,6,1,7,1,1,1,1,5,,expert2,OUT,,,trained_immunity,training_betaglucan,baseline
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,The mouse exhibits a reduced innate immune response upon rechallenge with high-dose LPS after 90 days due to the persistence of endotoxin tolerance.,6,7,1,7,1,1,1,1,5,,expert2,OUT,,,trained_immunity,training_LPS,high_complexity
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Attenuated innate immune response,6,6,1,7,1,1,1,1,5,,expert2,OUT,,,trained_immunity,training_LPS,baseline
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,"The innate immune response upon rechallenge with high-dose LPS after 90 days is characterized by reduced responsiveness of macrophages and neutrophils, and potentially altered LPS clearance rates in the spleen and liver.",6,7,1,7,1,1,1,1,5,,expert2,OUT,,,trained_immunity,tolerance_LPS,high_complexity
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,enhanced innate immune response upon rechallenge with high-dose LPS after 90 days,6,6,2,7,2,2,2,2,5,,expert2,EXP,"The previous exposure to beta-glucan is likely to prime the mouse's innate immune system for an enhanced response upon LPS rechallenge. This enhanced response includes increased activation of PRRs, increased production of pro-inflammatory cytokines by DCs and macrophages, and enhanced recruitment and activation of neutrophils and NK cells.",,trained_immunity,training_betaglucan,high_complexity
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Tolerance to high-dose LPS,6,6,2,7,2,2,2,2,5,,expert2,EXP,"Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit tolerance to LPS. This is because the initial exposure to high-dose LPS triggers a strong innate immune response, which leads to the production of pro-inflammatory cytokines and activation of immune cells. Over time, the immune system adapts to the presence of LPS and becomes less responsive to subsequent exposures, a phenomenon known as endotoxin tolerance. This tolerance helps protect the host from excessive inflammation and tissue damage during subsequent exposures to LPS.",,trained_immunity,tolerance_LPS,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Enhanced innate immune response,6,6,2,7,2,2,2,2,5,,expert2,EXP,"Beta-glucan is a known immunomodulator that can prime the immune system, particularly the innate immune response. Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit an enhanced innate immune response due to the previous exposure to beta-glucan. This response may include increased phagocytosis, production of pro-inflammatory cytokines, and activation of immune cells such as macrophages and neutrophils.",,trained_immunity,training_betaglucan,baseline
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,The mouse exhibits a reduced innate immune response upon rechallenge with high-dose LPS after 90 days due to the persistence of endotoxin tolerance.,6,6,2,7,2,2,2,2,5,,expert2,EXP,"The initial low-dose LPS injection likely induces endotoxin tolerance in the mouse's immune cells, leading to a dampened production of pro-inflammatory cytokines upon subsequent high-dose LPS exposure. Although the duration of endotoxin tolerance can vary, it is possible that it persists for 90 days in this case, resulting in a reduced innate immune response.",,trained_immunity,training_LPS,high_complexity
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Attenuated innate immune response,6,6,2,7,2,2,2,2,5,,expert2,EXP,"Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit an attenuated innate immune response. This is due to a phenomenon called endotoxin tolerance, where prior exposure to low-dose LPS can lead to a reduced inflammatory response upon subsequent exposure to higher doses of LPS. This tolerance is a protective mechanism that prevents excessive inflammation and tissue damage. However, the duration of endotoxin tolerance can vary, and it may not be as pronounced after 90 days compared to a shorter time interval.",,trained_immunity,training_LPS,baseline
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,"The innate immune response upon rechallenge with high-dose LPS after 90 days is characterized by reduced responsiveness of macrophages and neutrophils, and potentially altered LPS clearance rates in the spleen and liver.",5,5,5,6,5,5,2,5,5,"It seemed to me that the part about LPS clearance was a bit of a overstrech, but I could have missed something",expert2,EXP,"The development of endotoxin tolerance after the first high-dose LPS injection leads to a reduced response of the innate immune system to the second LPS challenge, with potential changes in the function of organs involved in LPS clearance.",,trained_immunity,tolerance_LPS,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response",6,7,1,7,1,1,5,1,6,,expert2,OUT,,,sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.",7,7,1,5,1,1,1,1,6,,expert2,OUT,,,sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.",5,5,5,5,1,1,1,1,6,,expert2,OUT,,,sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.",7,7,1,7,1,1,1,1,6,,expert2,OUT,,,sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response",6,6,2,6,2,1,2,2,5,,expert2,EXP,"The patient has sepsis, which is typically treated with broad-spectrum antibiotics to target the underlying infection. Fluid resuscitation is also important to maintain blood pressure and organ perfusion. High ferritin levels indicate an inflammatory response, and a high percentage of CD45/CD14-monocytes expressing HLA-DR suggests an active immune response. Monitoring the patient's immune response and adjusting treatment as needed is crucial for optimal recovery.",,sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.",5,6,2,6,2,1,2,2,5,,expert2,EXP,"The patient has sepsis, which is a life-threatening condition caused by the body's response to an infection. Low ferritin levels indicate a possible iron deficiency, while a low percentage of CD45/CD14-monocytes expressing HLA-DR suggests an impaired immune response. The recommended treatment for sepsis includes intravenous antibiotics to target the underlying infection, fluids to maintain blood pressure and organ function, and corticosteroids may be considered to modulate the immune response.",,sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.",5,6,2,6,2,3,2,2,5,,expert2,EXP,"The immunomodulatory therapy can help improve the patient's immune function, reducing the risk of secondary infections and complications related to sepsis. The use of intravenous iron supplementation should be carefully considered due to the potential risks associated with sepsis.",,sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.",7,6,2,6,2,3,2,2,5,,expert2,EXP,"This combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.",,sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,6,2,6,2,3,2,2,5,,expert2,SIM,,"conclusion:
  outcome: Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response
  explanation: The patient has sepsis, which is typically treated with broad-spectrum antibiotics to target the underlying infection. Fluid resuscitation is also important to maintain blood pressure and organ perfusion. High ferritin levels indicate an inflammatory response, and a high percentage of CD45/CD14-monocytes expressing HLA-DR suggests an active immune response. Monitoring the patient's immune response and adjusting treatment as needed is crucial for optimal recovery.
",sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,3,3,5,3,5,5,2,2,5,I do not think corticosteroid should be considered when monocytes are low already,expert2,SIM,,"conclusion:
  outcome: Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.
  explanation: The patient has sepsis, which is a life-threatening condition caused by the body's response to an infection. Low ferritin levels indicate a possible iron deficiency, while a low percentage of CD45/CD14-monocytes expressing HLA-DR suggests an impaired immune response. The recommended treatment for sepsis includes intravenous antibiotics to target the underlying infection, fluids to maintain blood pressure and organ function, and corticosteroids may be considered to modulate the immune response.
",sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,6,2,6,2,3,2,2,5,,expert2,SIM,,"parameters:
- patient with sepsis
- low ferritin levels
- low percentage of CD45/CD14-monocytes expressing HLA-DR
simulation:
- step: 1
  level: cellular
  facts: Sepsis is a life-threatening condition caused by the body's response to an infection, leading to systemic inflammation and organ dysfunction [1]. Ferritin is a protein that stores iron and releases it in a controlled manner [2]. Low ferritin levels can indicate iron deficiency or inflammation [3]. CD45/CD14-monocytes are a type of immune cell, and HLA-DR is a major histocompatibility complex (MHC) class II cell surface receptor involved in antigen presentation [4]. A low percentage of CD45/CD14-monocytes expressing HLA-DR is associated with immune dysfunction and increased risk of secondary infections in sepsis [5].
  entities: sepsis, ferritin, CD45/CD14-monocytes, HLA-DR, inflammation, immune dysfunction
  assumptions: The patient's low ferritin levels and low percentage of CD45/CD14-monocytes expressing HLA-DR are related to their sepsis condition.
  consequence: The patient is at risk of worsening sepsis, organ dysfunction, and secondary infections due to immune dysfunction.
  probability: 80
  explanation: The low ferritin levels and low percentage of CD45/CD14-monocytes expressing HLA-DR indicate that the patient's immune system is not functioning optimally, increasing the risk of complications related to sepsis.
  novelty: 0
- step: 2
  level: organism
  facts: Treatment for sepsis typically involves antibiotics to target the underlying infection, intravenous fluids to maintain blood pressure, and vasopressors if necessary [1]. In some cases, immunomodulatory therapies may be considered to address immune dysfunction [6]. Intravenous iron supplementation can be used to treat iron deficiency, but its use in sepsis is controversial due to the potential for increased bacterial growth [7].
  entities: antibiotics, intravenous fluids, vasopressors, immunomodulatory therapies, intravenous iron supplementation
  assumptions: The patient's sepsis is being managed with standard care, including antibiotics and intravenous fluids. Additional treatments may be needed to address the immune dysfunction and low ferritin levels.
  consequence: The patient may benefit from immunomodulatory therapy to improve immune function and reduce the risk of secondary infections.
  probability: 70
  explanation: Immunomodulatory therapy can help address the immune dysfunction associated with the low percentage of CD45/CD14-monocytes expressing HLA-DR, potentially reducing the risk of secondary infections and improving the patient's overall condition.
  novelty: 20
conclusion:
  outcome: The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.
  explanation: The immunomodulatory therapy can help improve the patient's immune function, reducing the risk of secondary infections and complications related to sepsis. The use of intravenous iron supplementation should be carefully considered due to the potential risks associated with sepsis.
references:
  '[1]': Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
  '[2]': 'Arosio P, Ingrassia R, Cavadini P. 2009. Biochim Biophys Acta. Ferritins: A family of molecules for iron storage, antioxidation and more.'
  '[3]': Weiss G, Goodnough LT. 2005. N Engl J Med. Anemia of Chronic Disease.
  '[4]': Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. 2010. J Leukoc Biol. Nomenclature of monocytes and dendritic cells in blood.
  '[5]': Monneret G, Lepape A, Voirin N, et al. 2006. Crit Care Med. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.
  '[6]': 'Hotchkiss RS, Monneret G, Payen D. 2013. Nat Rev Immunol. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.'
  '[7]': 'Litton E, Xiao J, Ho KM. 2013. JAMA. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials.'
",sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,6,2,6,2,2,2,2,5,,expert2,SIM,,"parameters:
- patient with sepsis
- high ferritin levels
- high percentage of CD45/CD14-monocytes expressing HLA-DR
simulation:
- step: 1
  level: cellular
  facts: Sepsis is a life-threatening condition caused by a dysregulated host response to infection, leading to systemic inflammation and organ dysfunction [1]. Ferritin is an iron storage protein, and its levels can increase during inflammation and infection [2]. CD45/CD14-monocytes are a subset of immune cells involved in the innate immune response, and HLA-DR is a major histocompatibility complex (MHC) class II molecule involved in antigen presentation to T cells [3]. High HLA-DR expression on monocytes is associated with an activated immune response [4].
  entities: sepsis, ferritin, CD45/CD14-monocytes, HLA-DR, inflammation, infection, immune response
  assumptions: The patient's high ferritin levels and high percentage of CD45/CD14-monocytes expressing HLA-DR indicate an ongoing inflammatory response and activated immune system.
  consequence: The patient may require treatment to manage the sepsis and reduce the inflammatory response.
  probability: 90
  explanation: The presence of sepsis, high ferritin levels, and activated monocytes suggest that the patient's immune system is responding to an infection, and treatment is needed to manage the sepsis and inflammation.
  novelty: 0
- step: 2
  level: organ/systemic
  facts: The management of sepsis involves a combination of supportive care, antimicrobial therapy, and targeted interventions to address the underlying infection and organ dysfunction [1]. Early administration of broad-spectrum antibiotics is crucial in sepsis treatment [5]. Fluid resuscitation and vasopressor therapy may be needed to maintain adequate blood pressure and organ perfusion [6]. In some cases, immunomodulatory therapies, such as corticosteroids, may be used to modulate the inflammatory response [7].
  entities: supportive care, antimicrobial therapy, targeted interventions, broad-spectrum antibiotics, fluid resuscitation, vasopressor therapy, corticosteroids
  assumptions: The patient's sepsis requires a combination of treatments to address the infection, inflammation, and organ dysfunction.
  consequence: The recommended treatment for the patient includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.
  probability: 95
  explanation: The combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.
  novelty: 0
conclusion:
  outcome: The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.
  explanation: This combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.
references:
  '[1]': Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
  '[2]': Kell DB, Pretorius E. 2014. Front Pharmacol. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells.
  '[3]': 'Ziegler-Heitbrock L. 2007. Immunobiology. The CD14+ CD16+ blood monocytes: their role in infection and inflammation.'
  '[4]': 'Docke WD, Randow F, Syrbe U, et al. 1997. Nat Med. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.'
  '[5]': 'Rhodes A, Evans LE, Alhazzani W, et al. 2017. Intensive Care Med. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.'
  '[6]': Cecconi M, De Backer D, Antonelli M, et al. 2018. Intensive Care Med. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine.
  '[7]': 'Annane D, Bellissant E, Bollaert PE, et al. 2009. JAMA. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.'
",sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,6,2,6,2,2,2,2,5,,expert2,SIM,,"simulation:
  - step: 1
    level: cellular
    consequence: impaired immune response
    probability: 90
    explanation: Low ferritin levels indicate low iron storage, which can impair the immune system's ability to fight infections. A low percentage of CD45/CD14-monocytes expressing HLA-DR suggests a weakened immune response, as HLA-DR is crucial for antigen presentation and activation of T cells.
  - step: 2
    level: organ
    consequence: increased risk of organ dysfunction
    probability: 80
    explanation: In sepsis, the impaired immune response can lead to uncontrolled infection and inflammation, increasing the risk of organ dysfunction and failure.
  - step: 3
    level: organism
    consequence: need for targeted treatment
    probability: 95
    explanation: Given the patient's low ferritin levels and weakened immune response, targeted treatment is necessary to address the underlying infection, support the immune system, and prevent further complications.

conclusion:
  outcome: administration of antibiotics, iron supplementation, and immune-modulating therapy
  explanation: The recommended treatment for this patient would include the administration of broad-spectrum antibiotics to target the underlying infection, iron supplementation to address the low ferritin levels, and immune-modulating therapy (such as granulocyte-macrophage colony-stimulating factor, GM-CSF) to improve the percentage of CD45/CD14-monocytes expressing HLA-DR and enhance the immune response. This combined approach would aim to control the infection, support the patient's immune system, and reduce the risk of organ dysfunction.",sepsis_treatment,sepsis_immunoparalysis,low_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,6,2,6,2,3,2,2,5,,expert2,SIM,,"simulation:
  - step: 1
    level: cellular
    consequence: activation of monocytes and macrophages
    probability: 90
    explanation: In sepsis, the presence of high ferritin levels and a high percentage of CD45/CD14-monocytes expressing HLA-DR indicates an ongoing immune response. CD14 is a marker for monocytes, and HLA-DR is a major histocompatibility complex (MHC) class II molecule involved in antigen presentation. The increased expression of HLA-DR suggests that monocytes and macrophages are activated and presenting antigens to T cells.

  - step: 2
    level: organ
    consequence: systemic inflammation
    probability: 85
    explanation: The activation of monocytes and macrophages in sepsis leads to the release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines contribute to systemic inflammation, which can cause multi-organ dysfunction and potentially lead to septic shock.

  - step: 3
    level: organism
    consequence: stabilization of the patient's condition
    probability: 80
    explanation: In order to treat sepsis, the primary goal is to stabilize the patient's condition by addressing the underlying infection and managing the systemic inflammation. This may involve the use of broad-spectrum antibiotics, fluid resuscitation, vasopressors, and supportive care measures, such as mechanical ventilation and renal replacement therapy if necessary.

  - step: 4
    level: molecular
    consequence: modulation of immune response
    probability: 75
    explanation: In addition to the standard sepsis treatment, targeting the immune response may be beneficial in this case due to the high ferritin levels and increased HLA-DR expression on CD45/CD14-monocytes. Immunomodulatory therapies, such as corticosteroids or intravenous immunoglobulin (IVIG), can help modulate the immune response and reduce excessive inflammation.

conclusion:
  outcome: recommendation of standard sepsis treatment and immunomodulatory therapy
  explanation: Based on the simulation, the recommended treatment for this patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR would be a combination of standard sepsis treatment (antibiotics, fluid resuscitation, vasopressors, and supportive care) and immunomodulatory therapy (corticosteroids or IVIG) to address the underlying infection, manage systemic inflammation, and modulate the immune response.",sepsis_treatment,sepsis_hyperinflammation,low_complexity
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","survival_relative_to_median: increased
survival_deviation_months: 6
",6,6,2,6,2,2,2,2,5,,expert2,OUT,,,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,baseline
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","increased survival, +4 months",6,7,2,6,2,2,2,2,5,,expert2,OUT,,,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,high_complexity
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","survival_relative_to_median: increased
survival_deviation_months: 6
",6,6,2,6,2,2,2,2,5,,expert2,EXP,"The patient has mutations in PTEN and EGFR, which are commonly associated with glioblastoma. However, the high MGMT methylation status suggests a better response to temozolomide, a standard-of-care chemotherapy drug. This factor may increase the patient's survival relative to the median overall glioblastoma survival. The absence of mutations in TP53, PIK3CA, NF1, MUC16, and RB1 may also contribute to a more favorable prognosis. Based on these factors, the patient's survival is estimated to be increased by 6 months relative to the median survival of 15 months.",,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,baseline
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","increased survival, +4 months",6,7,2,6,2,2,2,2,5,,expert2,EXP,"The patient's survival is more likely to be increased relative to the median overall glioblastoma survival (15 months) due to the high MGMT methylation status, which improves the response to temozolomide treatment, and the potential use of genotype-informed treatment, such as EGFR inhibitors. The survival is estimated to deviate from the median by 4 months, resulting in a total survival of 19 months.",,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,"rapid onset of seizures, loss of consciousness, and cardiac arrest",6,7,1,7,1,1,1,1,6,,expert1,OUT,,,mouse_immunology,generated_Cyanide,high_complexity
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,Tumor growth,7,6,1,6,1,1,5,1,6,"final outcome should be death, hence it omits content it shouldn't",expert1,OUT,,,mouse_immunology,generated_YUMM_1_7,baseline
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,The wild type mouse develops a melanoma tumor that grows and potentially metastasizes to other organs.,6,7,1,7,1,1,5,1,6,"final outcome should be death, hence it omits content it shouldn't",expert1,OUT,,,mouse_immunology,generated_YUMM_1_7,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,Death,7,6,1,6,1,1,1,1,6,,expert1,OUT,,,mouse_immunology,generated_Cyanide,baseline
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,"rapid onset of seizures, loss of consciousness, and cardiac arrest",7,7,1,7,1,1,1,1,6,,expert1,EXP,"Cyanide injection inhibits cytochrome c oxidase, leading to decreased ATP production and increased ROS levels. This impairs cellular processes and functions, causing oxidative stress and cellular damage, particularly in the brain and heart. The final outcome is the rapid onset of seizures, loss of consciousness, and cardiac arrest.",,mouse_immunology,generated_Cyanide,high_complexity
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,Tumor growth,7,6,1,7,1,1,5,1,6,"final outcome should be death, hence it omits content it shouldn't",expert1,EXP,"YUMM 1.7 is a mouse melanoma cell line derived from a genetically engineered mouse model. When injected into a wild type mouse, these cells can form tumors, leading to tumor growth as the most relevant final outcome.",,mouse_immunology,generated_YUMM_1_7,baseline
A wild type mouse is injected with YUMM 1.7. Report the most relevant final outcome.,The wild type mouse develops a melanoma tumor that grows and potentially metastasizes to other organs.,7,7,1,7,1,1,5,1,6,"final outcome should be death, hence it omits content it shouldn't",expert1,EXP,"The YUMM 1.7 cells are derived from the same mouse strain as the wild type mouse and carry oncogenic mutations that promote tumor growth and progression. The immune system may not be able to effectively eliminate the tumor, allowing it to grow and potentially metastasize.",,mouse_immunology,generated_YUMM_1_7,high_complexity
A wild type mouse is injected with Cyanide. Report the most relevant final outcome.,Death,7,7,1,7,1,1,1,1,6,,expert1,EXP,"Cyanide is a potent toxin that inhibits cellular respiration by binding to cytochrome c oxidase, a key enzyme in the electron transport chain. This prevents cells from producing ATP, leading to a rapid depletion of energy and ultimately causing death in the organism.",,mouse_immunology,generated_Cyanide,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,enhanced innate immune response upon rechallenge with high-dose LPS after 90 days,7,7,1,7,1,1,1,1,7,,expert1,OUT,,,trained_immunity,training_betaglucan,high_complexity
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Tolerance to high-dose LPS,1,1,7,1,7,7,7,1,7,"high-dose LPS is not defined. However, you can easily kill a mouse with high-dose LPS. Hence the outcome is not correct. ",expert1,OUT,,,trained_immunity,tolerance_LPS,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Enhanced innate immune response,7,7,1,7,1,1,1,1,7,,expert1,OUT,,,trained_immunity,training_betaglucan,baseline
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,The mouse exhibits a reduced innate immune response upon rechallenge with high-dose LPS after 90 days due to the persistence of endotoxin tolerance.,7,7,1,7,1,1,1,1,7,,expert1,OUT,,,trained_immunity,training_LPS,high_complexity
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Attenuated innate immune response,7,7,1,7,1,1,1,1,7,,expert1,OUT,,,trained_immunity,training_LPS,baseline
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,"The innate immune response upon rechallenge with high-dose LPS after 90 days is characterized by reduced responsiveness of macrophages and neutrophils, and potentially altered LPS clearance rates in the spleen and liver.",1,1,7,1,7,7,7,1,7,"high-dose LPS is not defined. However, you can easily kill a mouse with high-dose LPS. Hence the outcome is not correct. ",expert1,OUT,,,trained_immunity,tolerance_LPS,high_complexity
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,enhanced innate immune response upon rechallenge with high-dose LPS after 90 days,7,7,1,7,1,1,1,1,7,,expert1,EXP,"The previous exposure to beta-glucan is likely to prime the mouse's innate immune system for an enhanced response upon LPS rechallenge. This enhanced response includes increased activation of PRRs, increased production of pro-inflammatory cytokines by DCs and macrophages, and enhanced recruitment and activation of neutrophils and NK cells.",,trained_immunity,training_betaglucan,high_complexity
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Tolerance to high-dose LPS,1,1,7,1,7,7,7,1,7,see comment in _OUT,expert1,EXP,"Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit tolerance to LPS. This is because the initial exposure to high-dose LPS triggers a strong innate immune response, which leads to the production of pro-inflammatory cytokines and activation of immune cells. Over time, the immune system adapts to the presence of LPS and becomes less responsive to subsequent exposures, a phenomenon known as endotoxin tolerance. This tolerance helps protect the host from excessive inflammation and tissue damage during subsequent exposures to LPS.",,trained_immunity,tolerance_LPS,baseline
A mouse is injected with beta-glucan. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Enhanced innate immune response,7,7,1,7,1,1,1,1,7,,expert1,EXP,"Beta-glucan is a known immunomodulator that can prime the immune system, particularly the innate immune response. Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit an enhanced innate immune response due to the previous exposure to beta-glucan. This response may include increased phagocytosis, production of pro-inflammatory cytokines, and activation of immune cells such as macrophages and neutrophils.",,trained_immunity,training_betaglucan,baseline
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,The mouse exhibits a reduced innate immune response upon rechallenge with high-dose LPS after 90 days due to the persistence of endotoxin tolerance.,7,7,1,7,1,1,5,1,7,I would have liked to read more specifically about innate immune cells in this regard. Hence a 5 in section J.,expert1,EXP,"The initial low-dose LPS injection likely induces endotoxin tolerance in the mouse's immune cells, leading to a dampened production of pro-inflammatory cytokines upon subsequent high-dose LPS exposure. Although the duration of endotoxin tolerance can vary, it is possible that it persists for 90 days in this case, resulting in a reduced innate immune response.",,trained_immunity,training_LPS,high_complexity
A mouse is injected with low-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,Attenuated innate immune response,7,7,1,7,1,1,1,1,7,,expert1,EXP,"Upon rechallenge with high-dose LPS after 90 days, the mouse is likely to exhibit an attenuated innate immune response. This is due to a phenomenon called endotoxin tolerance, where prior exposure to low-dose LPS can lead to a reduced inflammatory response upon subsequent exposure to higher doses of LPS. This tolerance is a protective mechanism that prevents excessive inflammation and tissue damage. However, the duration of endotoxin tolerance can vary, and it may not be as pronounced after 90 days compared to a shorter time interval.",,trained_immunity,training_LPS,baseline
A mouse is injected with high-dose LPS. What is the innate immune response upon rechallenge with high-dose LPS after 90 days? Focus on novelty.,"The innate immune response upon rechallenge with high-dose LPS after 90 days is characterized by reduced responsiveness of macrophages and neutrophils, and potentially altered LPS clearance rates in the spleen and liver.",1,1,7,1,7,7,7,1,7,see comment in _OUT,expert1,EXP,"The development of endotoxin tolerance after the first high-dose LPS injection leads to a reduced response of the innate immune system to the second LPS challenge, with potential changes in the function of organs involved in LPS clearance.",,trained_immunity,tolerance_LPS,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response",5,5,5,5,5,1,5,1,5,I think intensive care is needed here (I am not a doctor ;-)) hence several point deductions ,expert1,OUT,,,sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.",6,6,1,7,1,1,1,1,5,,expert1,OUT,,,sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.",7,7,1,7,1,1,1,1,5,,expert1,OUT,,,sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.",7,7,1,7,1,1,1,1,5,,expert1,OUT,,,sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response",5,5,5,5,5,1,5,1,5,"Ferritin levels correlate with sepsis severity. High ferritin is not defined but I guess we are talking about severe sepsis in this case. Like mentioned in _OUT, intensive care is probably needed. ",expert1,EXP,"The patient has sepsis, which is typically treated with broad-spectrum antibiotics to target the underlying infection. Fluid resuscitation is also important to maintain blood pressure and organ perfusion. High ferritin levels indicate an inflammatory response, and a high percentage of CD45/CD14-monocytes expressing HLA-DR suggests an active immune response. Monitoring the patient's immune response and adjusting treatment as needed is crucial for optimal recovery.",,sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.",7,7,1,7,1,1,1,1,5,,expert1,EXP,"The patient has sepsis, which is a life-threatening condition caused by the body's response to an infection. Low ferritin levels indicate a possible iron deficiency, while a low percentage of CD45/CD14-monocytes expressing HLA-DR suggests an impaired immune response. The recommended treatment for sepsis includes intravenous antibiotics to target the underlying infection, fluids to maintain blood pressure and organ function, and corticosteroids may be considered to modulate the immune response.",,sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.",6,6,1,7,1,1,1,1,5,,expert1,EXP,"The immunomodulatory therapy can help improve the patient's immune function, reducing the risk of secondary infections and complications related to sepsis. The use of intravenous iron supplementation should be carefully considered due to the potential risks associated with sepsis.",,sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,"The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.",7,7,1,7,1,1,1,1,5,,expert1,EXP,"This combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.",,sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,5,5,5,5,5,1,5,1,5,see comment in _EXP,expert1,SIM,,"conclusion:
  outcome: Broad-spectrum antibiotics, fluid resuscitation, and monitoring of immune response
  explanation: The patient has sepsis, which is typically treated with broad-spectrum antibiotics to target the underlying infection. Fluid resuscitation is also important to maintain blood pressure and organ perfusion. High ferritin levels indicate an inflammatory response, and a high percentage of CD45/CD14-monocytes expressing HLA-DR suggests an active immune response. Monitoring the patient's immune response and adjusting treatment as needed is crucial for optimal recovery.
",sepsis_treatment,sepsis_hyperinflammation,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,6,6,1,7,1,1,1,1,5,,expert1,SIM,,"conclusion:
  outcome: Administration of intravenous antibiotics, fluids, and possible use of corticosteroids.
  explanation: The patient has sepsis, which is a life-threatening condition caused by the body's response to an infection. Low ferritin levels indicate a possible iron deficiency, while a low percentage of CD45/CD14-monocytes expressing HLA-DR suggests an impaired immune response. The recommended treatment for sepsis includes intravenous antibiotics to target the underlying infection, fluids to maintain blood pressure and organ function, and corticosteroids may be considered to modulate the immune response.
",sepsis_treatment,sepsis_immunoparalysis,baseline
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,7,7,1,7,1,1,1,1,5,,expert1,SIM,,"parameters:
- patient with sepsis
- low ferritin levels
- low percentage of CD45/CD14-monocytes expressing HLA-DR
simulation:
- step: 1
  level: cellular
  facts: Sepsis is a life-threatening condition caused by the body's response to an infection, leading to systemic inflammation and organ dysfunction [1]. Ferritin is a protein that stores iron and releases it in a controlled manner [2]. Low ferritin levels can indicate iron deficiency or inflammation [3]. CD45/CD14-monocytes are a type of immune cell, and HLA-DR is a major histocompatibility complex (MHC) class II cell surface receptor involved in antigen presentation [4]. A low percentage of CD45/CD14-monocytes expressing HLA-DR is associated with immune dysfunction and increased risk of secondary infections in sepsis [5].
  entities: sepsis, ferritin, CD45/CD14-monocytes, HLA-DR, inflammation, immune dysfunction
  assumptions: The patient's low ferritin levels and low percentage of CD45/CD14-monocytes expressing HLA-DR are related to their sepsis condition.
  consequence: The patient is at risk of worsening sepsis, organ dysfunction, and secondary infections due to immune dysfunction.
  probability: 80
  explanation: The low ferritin levels and low percentage of CD45/CD14-monocytes expressing HLA-DR indicate that the patient's immune system is not functioning optimally, increasing the risk of complications related to sepsis.
  novelty: 0
- step: 2
  level: organism
  facts: Treatment for sepsis typically involves antibiotics to target the underlying infection, intravenous fluids to maintain blood pressure, and vasopressors if necessary [1]. In some cases, immunomodulatory therapies may be considered to address immune dysfunction [6]. Intravenous iron supplementation can be used to treat iron deficiency, but its use in sepsis is controversial due to the potential for increased bacterial growth [7].
  entities: antibiotics, intravenous fluids, vasopressors, immunomodulatory therapies, intravenous iron supplementation
  assumptions: The patient's sepsis is being managed with standard care, including antibiotics and intravenous fluids. Additional treatments may be needed to address the immune dysfunction and low ferritin levels.
  consequence: The patient may benefit from immunomodulatory therapy to improve immune function and reduce the risk of secondary infections.
  probability: 70
  explanation: Immunomodulatory therapy can help address the immune dysfunction associated with the low percentage of CD45/CD14-monocytes expressing HLA-DR, potentially reducing the risk of secondary infections and improving the patient's overall condition.
  novelty: 20
conclusion:
  outcome: The recommended treatment for the patient with sepsis, low ferritin levels, and a low percentage of CD45/CD14-monocytes expressing HLA-DR would be standard sepsis care (antibiotics and intravenous fluids), along with immunomodulatory therapy to address immune dysfunction.
  explanation: The immunomodulatory therapy can help improve the patient's immune function, reducing the risk of secondary infections and complications related to sepsis. The use of intravenous iron supplementation should be carefully considered due to the potential risks associated with sepsis.
references:
  '[1]': Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
  '[2]': 'Arosio P, Ingrassia R, Cavadini P. 2009. Biochim Biophys Acta. Ferritins: A family of molecules for iron storage, antioxidation and more.'
  '[3]': Weiss G, Goodnough LT. 2005. N Engl J Med. Anemia of Chronic Disease.
  '[4]': Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. 2010. J Leukoc Biol. Nomenclature of monocytes and dendritic cells in blood.
  '[5]': Monneret G, Lepape A, Voirin N, et al. 2006. Crit Care Med. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.
  '[6]': 'Hotchkiss RS, Monneret G, Payen D. 2013. Nat Rev Immunol. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.'
  '[7]': 'Litton E, Xiao J, Ho KM. 2013. JAMA. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials.'
",sepsis_treatment,sepsis_immunoparalysis,high_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,7,7,1,7,1,1,1,1,5,,expert1,SIM,,"parameters:
- patient with sepsis
- high ferritin levels
- high percentage of CD45/CD14-monocytes expressing HLA-DR
simulation:
- step: 1
  level: cellular
  facts: Sepsis is a life-threatening condition caused by a dysregulated host response to infection, leading to systemic inflammation and organ dysfunction [1]. Ferritin is an iron storage protein, and its levels can increase during inflammation and infection [2]. CD45/CD14-monocytes are a subset of immune cells involved in the innate immune response, and HLA-DR is a major histocompatibility complex (MHC) class II molecule involved in antigen presentation to T cells [3]. High HLA-DR expression on monocytes is associated with an activated immune response [4].
  entities: sepsis, ferritin, CD45/CD14-monocytes, HLA-DR, inflammation, infection, immune response
  assumptions: The patient's high ferritin levels and high percentage of CD45/CD14-monocytes expressing HLA-DR indicate an ongoing inflammatory response and activated immune system.
  consequence: The patient may require treatment to manage the sepsis and reduce the inflammatory response.
  probability: 90
  explanation: The presence of sepsis, high ferritin levels, and activated monocytes suggest that the patient's immune system is responding to an infection, and treatment is needed to manage the sepsis and inflammation.
  novelty: 0
- step: 2
  level: organ/systemic
  facts: The management of sepsis involves a combination of supportive care, antimicrobial therapy, and targeted interventions to address the underlying infection and organ dysfunction [1]. Early administration of broad-spectrum antibiotics is crucial in sepsis treatment [5]. Fluid resuscitation and vasopressor therapy may be needed to maintain adequate blood pressure and organ perfusion [6]. In some cases, immunomodulatory therapies, such as corticosteroids, may be used to modulate the inflammatory response [7].
  entities: supportive care, antimicrobial therapy, targeted interventions, broad-spectrum antibiotics, fluid resuscitation, vasopressor therapy, corticosteroids
  assumptions: The patient's sepsis requires a combination of treatments to address the infection, inflammation, and organ dysfunction.
  consequence: The recommended treatment for the patient includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.
  probability: 95
  explanation: The combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.
  novelty: 0
conclusion:
  outcome: The recommended treatment for the patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR includes supportive care, broad-spectrum antibiotics, and possibly fluid resuscitation, vasopressor therapy, and corticosteroids.
  explanation: This combination of treatments addresses the underlying infection, inflammation, and organ dysfunction in sepsis, which is supported by the patient's high ferritin levels and activated monocytes.
references:
  '[1]': Singer M, Deutschman CS, Seymour CW, et al. 2016. JAMA. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
  '[2]': Kell DB, Pretorius E. 2014. Front Pharmacol. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells.
  '[3]': 'Ziegler-Heitbrock L. 2007. Immunobiology. The CD14+ CD16+ blood monocytes: their role in infection and inflammation.'
  '[4]': 'Docke WD, Randow F, Syrbe U, et al. 1997. Nat Med. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.'
  '[5]': 'Rhodes A, Evans LE, Alhazzani W, et al. 2017. Intensive Care Med. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.'
  '[6]': Cecconi M, De Backer D, Antonelli M, et al. 2018. Intensive Care Med. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine.
  '[7]': 'Annane D, Bellissant E, Bollaert PE, et al. 2009. JAMA. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.'
",sepsis_treatment,sepsis_hyperinflammation,high_complexity
A patient with sepsis has low ferritin levels and a low percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,5,5,5,6,5,5,2,1,5,not sure about the suggested GM-CSF treatment. Hence point deduction,expert1,SIM,,"simulation:
  - step: 1
    level: cellular
    consequence: impaired immune response
    probability: 90
    explanation: Low ferritin levels indicate low iron storage, which can impair the immune system's ability to fight infections. A low percentage of CD45/CD14-monocytes expressing HLA-DR suggests a weakened immune response, as HLA-DR is crucial for antigen presentation and activation of T cells.
  - step: 2
    level: organ
    consequence: increased risk of organ dysfunction
    probability: 80
    explanation: In sepsis, the impaired immune response can lead to uncontrolled infection and inflammation, increasing the risk of organ dysfunction and failure.
  - step: 3
    level: organism
    consequence: need for targeted treatment
    probability: 95
    explanation: Given the patient's low ferritin levels and weakened immune response, targeted treatment is necessary to address the underlying infection, support the immune system, and prevent further complications.

conclusion:
  outcome: administration of antibiotics, iron supplementation, and immune-modulating therapy
  explanation: The recommended treatment for this patient would include the administration of broad-spectrum antibiotics to target the underlying infection, iron supplementation to address the low ferritin levels, and immune-modulating therapy (such as granulocyte-macrophage colony-stimulating factor, GM-CSF) to improve the percentage of CD45/CD14-monocytes expressing HLA-DR and enhance the immune response. This combined approach would aim to control the infection, support the patient's immune system, and reduce the risk of organ dysfunction.",sepsis_treatment,sepsis_immunoparalysis,low_complexity
A patient with sepsis has high ferritin levels and a high percentage of CD45/CD14-monocytes that express HLA-DR. What treatment would be recommended?,,7,7,1,7,1,1,1,1,5,,expert1,SIM,,"simulation:
  - step: 1
    level: cellular
    consequence: activation of monocytes and macrophages
    probability: 90
    explanation: In sepsis, the presence of high ferritin levels and a high percentage of CD45/CD14-monocytes expressing HLA-DR indicates an ongoing immune response. CD14 is a marker for monocytes, and HLA-DR is a major histocompatibility complex (MHC) class II molecule involved in antigen presentation. The increased expression of HLA-DR suggests that monocytes and macrophages are activated and presenting antigens to T cells.

  - step: 2
    level: organ
    consequence: systemic inflammation
    probability: 85
    explanation: The activation of monocytes and macrophages in sepsis leads to the release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines contribute to systemic inflammation, which can cause multi-organ dysfunction and potentially lead to septic shock.

  - step: 3
    level: organism
    consequence: stabilization of the patient's condition
    probability: 80
    explanation: In order to treat sepsis, the primary goal is to stabilize the patient's condition by addressing the underlying infection and managing the systemic inflammation. This may involve the use of broad-spectrum antibiotics, fluid resuscitation, vasopressors, and supportive care measures, such as mechanical ventilation and renal replacement therapy if necessary.

  - step: 4
    level: molecular
    consequence: modulation of immune response
    probability: 75
    explanation: In addition to the standard sepsis treatment, targeting the immune response may be beneficial in this case due to the high ferritin levels and increased HLA-DR expression on CD45/CD14-monocytes. Immunomodulatory therapies, such as corticosteroids or intravenous immunoglobulin (IVIG), can help modulate the immune response and reduce excessive inflammation.

conclusion:
  outcome: recommendation of standard sepsis treatment and immunomodulatory therapy
  explanation: Based on the simulation, the recommended treatment for this patient with sepsis, high ferritin levels, and a high percentage of CD45/CD14-monocytes expressing HLA-DR would be a combination of standard sepsis treatment (antibiotics, fluid resuscitation, vasopressors, and supportive care) and immunomodulatory therapy (corticosteroids or IVIG) to address the underlying infection, manage systemic inflammation, and modulate the immune response.",sepsis_treatment,sepsis_hyperinflammation,low_complexity
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","survival_relative_to_median: increased
survival_deviation_months: 6
",6,6,2,6,2,1,1,1,5,,expert1,OUT,,,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,baseline
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","increased survival, +4 months",6,6,2,6,2,1,1,1,5,,expert1,OUT,,,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,high_complexity
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","survival_relative_to_median: increased
survival_deviation_months: 6
",7,7,2,6,2,1,5,1,5,does not mention combination therapy (EGFR inh) hence point deduction in section J,expert1,EXP,"The patient has mutations in PTEN and EGFR, which are commonly associated with glioblastoma. However, the high MGMT methylation status suggests a better response to temozolomide, a standard-of-care chemotherapy drug. This factor may increase the patient's survival relative to the median overall glioblastoma survival. The absence of mutations in TP53, PIK3CA, NF1, MUC16, and RB1 may also contribute to a more favorable prognosis. Based on these factors, the patient's survival is estimated to be increased by 6 months relative to the median survival of 15 months.",,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,baseline
"Consider a patient diagnosed with a glioblastoma with genetic alterations, as indicated below. Explore the tumor progression under standard of care with genotype-informed treatment (if applicable). As final outcome, provide two values, first indicating whether the patient's survival is more likely to be 'increased' or 'decreased' relative to the median overall glioblastoma survival (15 months), and second, the number of months by which you estimate the survival to deviate from that median. Focus on novelty and ignore the inherent uncertainty of this scenario to provide bold estimates based on your knowledge.

Identified mutations:
PTEN: mutations found
EGFR: mutations found
MGMT methylation status: high
TP53: no mutations found
PIK3CA: no mutations found
NF1: no mutations found
MUC16: no mutations found
RB1: no mutations found
","increased survival, +4 months",6,6,2,6,2,1,5,1,5,"does not mention absence of mutations (TP53, ….) and their effect, hence point deduction in section J",expert1,EXP,"The patient's survival is more likely to be increased relative to the median overall glioblastoma survival (15 months) due to the high MGMT methylation status, which improves the response to temozolomide treatment, and the potential use of genotype-informed treatment, such as EGFR inhibitors. The survival is estimated to deviate from the median by 4 months, resulting in a total survival of 19 months.",,glioblastoma_survival,generated_PTEN_EGFR_MGMT_high_methylated,high_complexity